Healthtech funding in Q4 2024
European Healthtech startup funding raised during Q4 2024.
In Q4 2024, 106 European Healthtech companies closed 107 funding rounds and raised €1.7B in equity funding (excluding debt and grants), up 124.7% versus Q4 2023. Debt rounds added €20M. Switzerland led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.7B
+124.7% vs Q4 2023 · excl. debt & grants · +€20M debt
Funding rounds
107
-11.6% vs Q4 2023
Companies
106
Top country
Switzerland
Rank among sectors
#3
12.5% of sector funding
Debt financing
€20M
1.1% of total
Top-10 round share
59.5%
of disclosed capital
Rounds ≥ €100M
2
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q4 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Oct | €431M | 27 |
| Nov | €407M | 40 |
| Dec | €916M | 40 |
Top countries
by € raisedHealthtech — top countries by capital, Q4 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, Q4 2024 | |
|---|---|
| Switzerland | €379M |
| UK | €343M |
| Finland | €266M |
| Netherlands | €192M |
| France | €114M |
| Belgium | €113M |
| Germany | €104M |
| Denmark | €93M |
Stage mix
by € raisedHealthtech — stage mix, Q4 2024 — interactive chart.
Data table
| Healthtech — stage mix, Q4 2024 | |
|---|---|
| Other | €529M |
| Series D+ | €433M |
| Series B | €360M |
| Series A | €251M |
| Seed | €101M |
| Series C | €46M |
| Debt | €20M |
| Pre-Seed | €12M |
Exits & M&A
2 Acquisition · 1 Merger3 exits · €50M disclosed.
| Lamidey Noury Medical | Acquisition | Nov 2024 | €50M |
Top deals
largest disclosed rounds in Q4 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| Cimeio Therapeutics | Other | Dec 2024 | €282M |
| ŌURA | Series D+ | Dec 2024 | €192M |
| Citryll | Series B | Dec 2024 | €85M |
| Agomab Therapeutics | Series D+ | Oct 2024 | €83M |
| Antag Therapeutics | Series A | Dec 2024 | €80M |
| ŌURA | Series D+ | Nov 2024 | €71M |
| Cradle | Series B | Nov 2024 | €69M |
| Nuclera | Series A | Oct 2024 | €69M |
| Quanta Dialysis Technologies | Series D+ | Nov 2024 | €57M |
| Basecamp Research | Series B | Oct 2024 | €55M |
| Inbrain Neuroelectronics | Series B | Oct 2024 | €46M |
| Aqemia | Other | Dec 2024 | €36M |
| Aignostics | Series B | Oct 2024 | €32M |
| Inotec Amd | Series C | Dec 2024 | €31M |
| Midiagnostics | Series D+ | Dec 2024 | €30M |
Top investors
most active in Q4 2024, by deal count- High-Tech Gründerfonds (HTGF)5 deals
- Luminar Ventures3 deals
- Mercia Ventures3 deals
- Redalpine3 deals
- SFC Capital3 deals
- Asabys Partners2 deals
- DexCom2 deals
- European Innovation Council (EIC)2 deals
- Export and Investment Fund of Denmark (EIFO)2 deals
- Forbion2 deals